Our results indicate that emapalumab is able to induce a significant reduction of CRS, HLH/MAS and brain damage, without impairing the anti-leukemia activity of CAR-T cells against CD19-positive B-cell malignancies. Here, CD19 is linked to congenital rubella syndrome.